Dr. Lekakis on Real-World Data With CAR T-Cell Therapy in Lymphoma

Video

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses real-world data with CAR T-cell therapy from the 2018 ASH Annual Meeting.

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses real-world data with CAR T-cell therapy from the 2018 ASH Annual Meeting.

The real-world data for the use of axicabtagene ciloleucel (axi-cel; Yescarta) came as a surprise to some physicians, says Lekakis. A lot of people in the community thought the ZUMA-1 trial data would not be reproducible in practice as there were very strict exclusion criteria for the study. However, the real-world data with over 200 patients showed a complete response rate that was consistent with the data from the ZUMA-1 trial.

Moreover, it was not the only trial that demonstrated those results in a real-world setting, says Lekakis. Taken collectively, these data show that approximately 37% of patients had no evidence of disease at the time of data cutoff. These patients are most likely cured because very few relapses happen after a 6-month cutoff, adds Lekakis.

Related Videos
Salvador Rico, MD, PhD, on Developing Gene Regulation Therapy for Dravet Syndrome
Leigh Ramos-Platt, MD, on Sharing Experience With Gene Therapy Administration
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
© 2024 MJH Life Sciences

All rights reserved.